Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts
<p>Abstract</p> <p>Background</p> <p>In around 50% of all human cancers the tumor suppressor p53 is mutated. It is generally assumed that in the remaining tumors the wild-type p53 protein is functionally impaired. The two main inhibitors of p53, hMDM2 (MDM2) and hMDMX (...
Main Authors: | van der Burg Marja JM, Wiercinska Eliza, Verlaan-de Vries Matty, Lodder Kirsten, Teunisse Amina FAS, de Lange Job, Lenos Kristiaan, Szuhai Karoly, Jochemsen Aart G |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://www.molecular-cancer.com/content/10/1/111 |
Similar Items
-
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
by: Zuzana Mrkvová, et al.
Published: (2019-06-01) -
Clinical overview of MDM2/X targeted therapies
by: Andrew eBurgess, et al.
Published: (2016-01-01) -
Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells
by: Chong Gao, et al.
Published: (2019-01-01) -
Controlling the Mdm2-Mdmx-p53 Circuit
by: David L. Waning, et al.
Published: (2010-05-01) -
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
by: De-Hua Yu, et al.
Published: (2020-08-01)